The Effect of Benign and Malignant Liver Disease on the Tumour Markers CA19-9 and CEA
Open Access
- 1 January 1998
- journal article
- research article
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 35 (1) , 99-103
- https://doi.org/10.1177/000456329803500113
Abstract
The serum concentrations of CA19-9 and carcinoembryonic antigen (CEA) were measured in 150 consecutive patients with histologically proven liver disease admitted to a liver unit for transplant assessment. A significant proportion of the cases studied had a CA19-9 above the upper limit of the reference range (35 kU/L): alcoholic liver disease (73%), primary sclerosing cholangitis (61%), primary biliary cirrhosis (60%), chronic hepatitis B (71%), chronic hepatitis C (84%), autoimmune hepatitis (36%) and hepatocellular carcinoma (54%). CEA was only elevated in a small proportion of the patients with benign liver disease and the degree of elevation was small (15-37 μg/L). Significantly raised CEA was observed in two patients (15%) with hepatocellular carcinoma. Statistically significant correlations were observed between the serum CA19-9 concentration and standard parameters of liver dysfunction: positive correlations with aspartate aminotransferase, alkaline phosphatase and bilirubin and negative correlations with albumin and γ-glutamyltransferase. Positive relationships were also observed between CA19-9 and both CEA and creatinine. Both increased production of CA19-9 from biliary epithelial cells and decreased clearance due to cholestasis may be contributing to the elevation of CA19-9 in the bloodstream. Our data indicate that caution is needed in the interpretation of CA19-9 results in the presence of liver dysfunction.Keywords
This publication has 13 references indexed in Scilit:
- CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEABritish Journal of Cancer, 1994
- Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction.Gut, 1994
- CA 19‐9 as a prognostic index after resection for pancreatic cancerJournal of Surgical Oncology, 1993
- Extra-hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseasesEuropean Journal of Clinical Investigation, 1992
- CA 19-9 in non-neoplastic liver diseases. A clinical and laboratory studyClinica Chimica Acta; International Journal of Clinical Chemistry, 1992
- CA 125 serum levels in patients with non-neoplastic liver diseases. A clinical and laboratory studyScandinavian Journal of Clinical and Laboratory Investigation, 1992
- Serum levels of carbohydrate antigenic determinant (CA 19.9) in obstructive jaundiceDigestive Diseases and Sciences, 1989
- Elevated serum levels of tumor marker CA19-9 in acute cholangitisDigestive Diseases and Sciences, 1988
- Elevation of CA 125 in patients with benign and malignant ascitesCancer, 1987
- Clinical Significance of Serum CA125 Values in Patients with Cancers of the Digestive SystemThe Lancet Healthy Longevity, 1986